Announcement • Mar 27
MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026 MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026. Location: 13 floor no,659, pan s. rd., jhonghe district, new taipei city Taiwan New Risk • Mar 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$3.01b market cap, or US$95.8m). New Risk • Jan 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (8.5% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$2.21b market cap, or US$69.8m). 
